View Mike Huckman's Articles BY TICKER:
- Biopharma: Instead of M&A, Think P&A
- How Can Both Genentech and Roche Rally?
- Roche Is Considerably Worse Off Without Genentech
- Genentech Overtakes Pfizer - Briefly
- After Thursday's Bloodbath, Is Biopharma a Buy?
- Pfizer: The F Is for February Failures
- CardioNet's Light Profit Forecast Is a Good Thing - Leerink Swann
Lilly Supersizes Its Board
Feb. 18, 2009 • Comment!
- Pfizer / Wyeth: The Dust's Still Settling
- Roche and Genentech: As the Deal Turns
- Biotechs: The Cash Crunch
- Roche Is Still Gunning for Genentech
- Merck Lets Its Gardasil Down
- Pfizer Scraps Pancreatic Cancer Drug
- Why the Drop in Roche's Genentech Bid?
- Pfizer Quits Ad Agency
- Lilly and Glaxo's Musical Chairs
- Sequenom Is Put to the Test
- Pfizer's Kindler Continues to Make His Case for Wyeth Merger
- Was Geron's Announcement Timed?
- JNJ Hurt by Soft Stent Sales
- Can Steve Jobs's Case Help Propel Biopharma?
- How Is the Biotech Industry Holding Up?
- Ladies Still in Waiting for Merck's Gardasil
- Cardinal Health, Intuitive Surgical Injured by the Economy
- A Bull's on the Loose at Elan
- What Will Brown Do for Merck?
- Is Pfizer Now Interested in a Merger?
- Will Lilly's Effient Make It Through FDA Review?
- Pharma Stocks Buck the Market Trend
Pfizer, the CIA and a Slow News Day
Dec. 26, 2008 • 2 Comments
- Vertex's $75K Question